查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2011313

癌症生物標記市場：按生物標記類型、技術、癌症類型、檢測類型、應用和最終用戶分類－2026-2032年全球市場預測

Cancer Biomarkers Market by Biomarker Type, Technology, Cancer Type, Test Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，癌症生物標記市場價值將達到 346.6 億美元，到 2026 年將成長至 381.3 億美元，到 2032 年將達到 724.1 億美元，複合年成長率為 11.09%。

主要市場統計數據
基準年 2025 346.6億美元
預計年份：2026年 381.3億美元
預測年份 2032 724.1億美元
複合年成長率 (%) 11.09%

為了應對癌症治療中高風險和高精度的要求，需要策略性地採用生物標記來改變診斷、治療和轉化流程。

癌症生物標記正以日益精準的方式將分子層面的資訊與患者照護結合，從而重新定義臨床決策。過去十年，分子生物學、檢測靈敏度和計算分析的進步，已使生物標記從回顧性研究工具轉變為前瞻性的診斷、預後和治療方法選擇指南。因此，參與藥物研發、轉化科學、診斷開發和臨床應用的相關人員需要重新思考其策略，以最大限度地利用技術融合和不斷變化的監管環境帶來的益處。

透過整合科學進步、數據驅動的解釋和策略夥伴關係，我們正在全面改變生物標記從發現到臨床實踐的過程。

在科學突破、技術成熟和臨床需求不斷變化等因素的推動下，癌症生物標記研發領域正經歷著變革性的轉變。基因組技術，特別是那些能夠進行全面核酸分析和表觀表觀基因分析的技術，已經從純粹的研究領域走向了常規的臨床工作流程。同時，蛋白質體學和代謝組學檢測技術正透過靶向質譜的化學特性和改進的免疫檢測方法，提高診斷的特異性。這些技術的共同作用，使得多模態生物標記策略更能準確地反映腫瘤的異質性。

到 2025 年，關稅政策的變化將如何重塑整個腫瘤生物標記生態系統的採購、製造韌性和區域籌資策略？

2025年實施的新關稅政策引入了複雜的貿易考量因素，將對診斷試劑和儀器的供應鏈、籌資策略和成本結構產生影響。雖然貿易措施本身不會改變科學原理，但它們會對採購決策以及生產和組裝的地理位置產生重大影響。依賴全球採購的試劑、專有耗材和高價值分析儀器的企業需要重新評估其供應商多元化、庫存策略和物流系統，以維持業務永續營運。

將生物標記模式、平台功能、臨床應用、最終用戶需求、癌症亞型特異性和採樣方法與策略決策聯繫起來的全面細分見解。

細分分析揭示了不同技術平台、分析物分類、臨床應用、終端用戶、癌症類型和檢測方式之間的細微機會和限制因素。根據基於生物標記類型的細分，細胞生物標記在腫瘤免疫學應用中仍然至關重要，而包括DNA、表觀遺傳標記以及多種RNA類別（例如長鏈非編碼RNA、傳訊RNA和微型RNA）在內的遺傳生物標記，則提供了多層次的訊號，支持診斷鑑別和預測建模。代謝和蛋白質生物標記在功能和通路層面提供了互補的訊息，從而增強了基於多樣檢體分析的決策。

監管細微差別、臨床基礎設施和市場進入趨勢的關鍵區域觀點將決定生物標記創新如何在全球醫療保健系統中擴展。

區域趨勢在塑造研發路徑、監管策略和部署計畫方面發揮著至關重要的作用。在美洲，完善的臨床研究基礎設施和先進的支付方環境促進了高度複雜的診斷和伴隨檢測的早期應用，而集中式檢查室網路則支援在各種醫療機構中進行可擴展的部署。在歐洲、中東和非洲，特定市場的監管趨同和多樣化的報銷框架為有針對性的上市策略創造了機遇，同時也需要量身定做證據包，以滿足各國特定的醫療技術評估要求。在亞太地區，對定序和診斷能力的快速投資，加上龐大且多樣化的患者群體，為產生真實世界證據提供了沃土，但監管預期和當地生產能力的差異會影響市場進入計劃。

從企業層面洞察垂直整合、跨產業夥伴關係和平台差異化，進而決定生物標記領域的競爭優勢。

生物標記生態系統的競爭動態呈現出多元化的態勢，既有成熟的診斷試劑生產商，也有敏捷的生物技術研發公司、專業儀器製造商以及服務型檢查室網路。主要企業正透過投資整合平台來實現差異化競爭，這些平台將高通量分子分析與先進的生物資訊學相結合，從而縮短結果出具時間並實現更豐富的臨床註釋。同時，許多機構正致力於垂直整合，以管理試劑生產、檢測方法製造和基於軟體的結果解讀等關鍵供應鏈環節，從而降低對其他環節的依賴並提高品質保證水準。

將多參數分析技術、彈性供應鏈和符合支付方需求的證據產生整合到可行的商業化藍圖。

行業領導者應制定一系列切實可行的優先事項，以協調科學能力、監管準備和商業性可行性。首先，優先發展結合基因組學、蛋白質組學和代謝訊號的多分析物方法，以提高診斷準確性並應對腫瘤異質性。透過設計具有互補模式的檢測方法，機構可以提高臨床相關性，並減少對單一分析結果的依賴。其次，投資於支援可擴展解讀、聯合資料共用和機器學習模型整合的資料基礎設施和生物資訊學流程，同時保持嚴格的資料管治和隱私保護。

我們採用透明的三角測量調查方法，結合相關人員訪談、同儕審查文獻和監管指導，得出可靠且可操作的見解。

本研究採用三角調查方法，結合了質性訪談、文獻回顧以及監管和臨床指南的結構化整合。主要資訊來源包括與轉化研究、診斷開發、臨床實驗室運作以及支付方諮詢等領域的相關人員進行討論，以了解實際限制和策略重點。二級資訊來源包括同行評審文獻、已發布的監管指南、臨床試驗註冊數據和技術白皮書，以確保科學準確性並闡明技術能力。

簡而言之：整合科學方法、營運韌性和實證策略是生物標記開發未來成功的關鍵因素。

總之，癌症生物標記領域正處於一個關鍵的轉折點，只有當科學創新、技術融合和商業性應用三者協調一致時，才能真正實現其臨床價值。最有前景的進展將源於整合多種方法，這些方法利用基因組學、蛋白質組學、代謝組學和細胞層面的訊號傳導，以及能夠在任何臨床環境下提供可重複且可解釋結果的平台技術。同時，貿易政策、區域監管差異和支付方期望等外部因素正在對創新技術的應用方式和應用領域產生決定性影響。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 癌症生物標記市場：依生物標記類型分類

  • 細胞生物標記
  • 基因生物標記
    • DNA生物標記
    • 表觀遺傳生物標記
    • RNA生物標記
      • 長鏈非編碼RNA
      • 傳訊RNA
      • 微型RNA
  • 代謝生物標記
  • 蛋白質生物標記

第9章：癌症生物標記市場：依技術分類

  • 酵素免疫分析法
  • 流式細胞技術
  • 質譜分析
  • 次世代定序
  • 聚合酵素鏈鎖反應

第10章：以癌症類型分類的癌症生物標記市場

  • 乳癌
  • 結腸癌
  • 肺癌
  • 卵巢癌
  • 攝護腺癌

第11章 依檢測類型分類的癌症生物標記市場

  • 液態生物檢體
  • 組織切片檢查

第12章 癌症生物標記市場：依應用領域分類

  • 伴隨診斷
  • 診斷
  • 監測
  • 預測性測試
  • 預後診斷

第13章 癌症生物標記市場：依最終用戶分類

  • 學術研究機構
  • 生技公司
  • 合約研究機構
  • 診斷檢測實驗室
  • 醫院
  • 製藥公司

第14章 癌症生物標記市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 癌症生物標記市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 癌症生物標記市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國癌症生物標記市場

第18章：中國癌症生物標記市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Caris Life Sciences
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd
  • Foundation Medicine, Inc.
  • Guardant Health, Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • NeoGenomics Laboratories, Inc.
  • PerkinElmer, Inc.
  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • Siemens Healthineers AG
  • SomaLogic, Inc.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-437517DB6E4D

The Cancer Biomarkers Market was valued at USD 34.66 billion in 2025 and is projected to grow to USD 38.13 billion in 2026, with a CAGR of 11.09%, reaching USD 72.41 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 34.66 billion
Estimated Year [2026] USD 38.13 billion
Forecast Year [2032] USD 72.41 billion
CAGR (%) 11.09%

High stakes and high precision in oncology demand a strategic introduction to how biomarkers are reshaping diagnostics, therapies, and translational pipelines

Cancer biomarkers are redefining clinical decision-making by linking molecular insight to patient care in increasingly precise ways. Over the last decade, advances in molecular biology, assay sensitivity, and computational analytics have shifted biomarkers from retrospective research tools to prospective guides for diagnosis, prognosis, and therapeutic selection. As a result, stakeholders across discovery, translational science, diagnostic development, and clinical delivery must recalibrate their strategies to capitalize on technological convergence and regulatory evolution.

In addition, the expanding repertoire of analytes and platforms has created new interfaces between laboratory science and point-of-care practice. Today, multi-analyte approaches that combine genetic, proteomic, metabolic, and cellular signals are enabling richer phenotypic resolution, while iterative improvements in next generation sequencing, mass spectrometry, and high-sensitivity immunoassays are driving assay robustness. Consequently, organizations are compelled to integrate cross-disciplinary expertise spanning bioinformatics, clinical operations, and commercial access to translate biomarker discoveries into validated clinical tools.

Finally, the introduction of companion diagnostics, the growing clinical acceptance of liquid biopsy, and heightening payer scrutiny all underscore the need for rigorous evidentiary pathways. For stakeholders aiming to lead in this space, the strategic challenge is twofold: to prioritize biomarker candidates and technologies with the highest potential clinical utility, and to construct pragmatic development plans that incorporate regulatory strategy, reimbursement considerations, and scalable manufacturing. This executive summary distills those imperatives and offers actionable direction for decision-makers seeking to accelerate evidence-to-impact timelines.

An integrated view of scientific advances, data-driven interpretation, and strategic partnerships that are collectively transforming how biomarkers advance from discovery to clinical practice

The landscape of cancer biomarker development is undergoing transformative shifts driven by scientific breakthroughs, technological maturation, and evolving clinical expectations. Genomic technologies, particularly those enabling comprehensive nucleic acid analysis and epigenomic profiling, have moved from research-only environments into routine clinical workflows. At the same time, proteomic and metabolic assays have improved their diagnostic specificity through targeted mass spectrometry and enhanced immunoassay chemistries, which together enable multi-modal biomarker strategies that better capture tumor heterogeneity.

Concurrently, analytics and data integration are reshaping interpretation frameworks. Advanced bioinformatics pipelines and machine learning approaches now facilitate signal deconvolution from complex biological matrices, improving the translation of raw assay outputs into clinically actionable information. Regulatory agencies have responded by clarifying expectations for clinical validation and real-world performance, prompting developers to design studies that combine analytical validity with demonstrable clinical utility. As a result, development timelines and evidentiary strategies are increasingly structured around adaptive validation paradigms that can incorporate real-world data and iterative refinements.

Finally, market dynamics are shifting toward collaboration across traditionally siloed stakeholders. Strategic partnerships now commonly span academic research centers, diagnostic laboratories, biotechnology firms, and pharmaceutical companies to accelerate the co-development of assays and therapeutics. These alliances are increasingly necessary to align assay design with therapeutic mechanisms and to ensure that companion diagnostic development progresses in step with drug development. Together, these shifts are elevating the importance of integrated translational planning, aligning scientific discovery with clinical implementation and commercial viability.

How evolving tariff policies in 2025 are reshaping procurement, manufacturing resiliency, and regional sourcing strategies across the oncology biomarker ecosystem

New tariff policies in 2025 have introduced a complex overlay of trade considerations that affect supply chains, procurement strategies, and cost structures for diagnostic reagents and instrumentation. Although trade measures do not alter the underlying science, they materially influence sourcing decisions and the geography of manufacturing and assembly. Organizations that depend on globally sourced reagents, proprietary consumables, and high-value analytical instruments must now reassess supplier diversification, inventory strategies, and logistics to maintain continuity of operations.

In response, many diagnostic developers and clinical laboratories are reprioritizing near-shore manufacturing and qualifying alternative suppliers to mitigate exposure to cross-border tariff volatility. This rebalancing often incurs short-term operational friction but can reduce long-term supply risk. At the same time, procurement teams are redesigning contracts to incorporate clauses that address tariff-triggered cost fluctuations and to secure multi-year agreements that can provide pricing stability for essential reagents and instruments. Consequently, capital planning and pricing strategies for assay launches are increasingly informed by sensitivity analyses tied to tariff scenarios rather than solely by assay performance metrics.

Furthermore, these trade dynamics are shaping regional research collaborations and investment flows. Institutions and companies gravitate toward regulatory jurisdictions and manufacturing hubs that offer both tariff predictability and favorable infrastructure for clinical trials and diagnostic production. As a result, the cumulative impact of the tariffs is not uniform; it magnifies existing disparities in manufacturing capacity and can accelerate decisions to relocate certain production stages. Ultimately, the most resilient organizations will be those that combine supply chain agility with strategic sourcing, while maintaining transparent communication with clinical partners and payers to manage transitions without compromising patient access.

Holistic segmentation insights linking biomarker modality, platform capabilities, clinical application, end user requirements, cancer subtype specificity, and sampling modality to strategic decision-making

Segmentation analysis reveals nuanced opportunities and constraints across technology platforms, analyte classes, clinical applications, end users, cancer types, and test modalities. Biomarker type segmentation shows that cellular biomarkers remain critical for immuno-oncology applications, while genetic biomarkers - encompassing DNA, epigenetic markers, and multiple RNA classes such as long non-coding RNA, messenger RNA, and microRNA - present layered signals that support both diagnostic discrimination and predictive modeling. Metabolic and protein biomarkers provide complementary functional and pathway-level context that strengthens multi-analyte decision-making.

Technology-driven segmentation indicates that enzyme linked immunosorbent assay retains a role for focused protein quantification, flow cytometry supports cellular phenotyping in both research and clinical labs, and mass spectrometry delivers high-specificity proteomic and metabolomic readouts. Next generation sequencing excels for broad genomic and transcriptomic profiling, while polymerase chain reaction remains indispensable for targeted, rapid nucleic acid detection. These technologies are not mutually exclusive; rather, strategic combinations can optimize sensitivity, specificity, turnaround time, and cost-effectiveness depending on clinical intent.

Application-based segmentation clarifies that companion diagnostics require the tightest alignment with therapeutic development and regulatory pathways, diagnostics demand robust analytical validity, while monitoring, predictive testing, and prognostics each impose distinct requirements for longitudinal performance, clinical interpretability, and integration with electronic health records. End user segmentation highlights diverse adoption contexts: academic research institutes prioritize innovation and exploratory validation, biotechnology companies drive translational product development, contract research organizations support scalable validation workflows, diagnostic laboratories focus on reproducible clinical assays, hospitals demand operational reliability and integration with clinical workflows, and pharmaceutical companies prioritize companion diagnostic co-development to de-risk therapeutic launches.

Cancer type segmentation underscores disease-specific biomarker performance considerations; breast, colorectal, lung, ovarian, and prostate cancers each exhibit unique molecular landscapes and clinical pathways that influence assay design and utility. Test type segmentation - liquid biopsy versus tissue biopsy - frames trade-offs between minimally invasive longitudinal monitoring and the comprehensive spatial context provided by tissue-based assays. Taken together, these segmentation lenses suggest that the most impactful strategies will merge analyte- and technology-specific strengths with application-driven evidentiary plans tailored to the clinical environment and cancer subtype.

Critical regional perspectives on regulatory nuance, clinical infrastructure, and market access dynamics that determine how biomarker innovations scale across global healthcare systems

Regional dynamics play a pivotal role in shaping development pathways, regulatory strategy, and adoption timelines. In the Americas, strong clinical research infrastructure and an advanced payer environment drive early adoption of high-complexity diagnostics and companion tests, while centralized laboratory networks support scalable deployment across diverse care settings. In Europe, Middle East & Africa, regulatory convergence in certain markets and heterogeneity in reimbursement frameworks create both opportunities for targeted launch strategies and the need for tailored evidence packages that address country-specific health technology assessment requirements. In the Asia-Pacific region, rapid investments in sequencing and diagnostic capacity, coupled with large and diverse patient populations, create fertile ground for real-world evidence generation, though variations in regulatory expectations and local manufacturing capabilities influence go-to-market planning.

Across these regions, cross-border collaborations and multi-jurisdictional clinical programs are increasingly common, enabling broader data capture and more robust validation studies. However, trade considerations and regional manufacturing capacity can alter the cost and timing of assay availability in specific markets. As a consequence, developers must adopt region-specific regulatory strategies, harmonize data collection frameworks, and prioritize local clinical partnerships to facilitate adoption and to generate the payer evidence necessary for coverage decisions. In short, regional nuance matters: global ambitions succeed only when regional operational plans, regulatory engagement, and reimbursement pathways are synchronized.

Strategic company-level insights on vertical integration, cross-sector partnerships, and platform differentiation that define competitive advantage in the biomarker landscape

Competitive dynamics in the biomarker ecosystem reflect a mix of incumbent diagnostics manufacturers, agile biotechnology developers, specialized instrument makers, and service-oriented laboratory networks. Leading players are differentiating through investments in integrated platforms that combine high-throughput molecular analysis with advanced bioinformatics, enabling faster time-to-result and richer clinical annotation. At the same time, many organizations are focusing on vertical integration to control critical supply chain elements such as reagent production, assay manufacturing, and software-enabled interpretation, thereby reducing dependencies and improving quality assurance.

Strategic collaborations are a common theme: partnerships between diagnostics developers and pharma companies accelerate companion diagnostic co-development, while alliances with academic centers facilitate access to clinical cohorts and translational expertise. Contract research organizations and centralized diagnostic laboratories play a vital role in scaling validation studies and in commercial rollouts, offering flexible capacity and regulatory experience. Additionally, some companies are pursuing modular commercial strategies that separate assay kits, instrument placement, and interpretation services, enabling multiple revenue streams and broader clinical reach.

In this competitive environment, companies that prioritize interoperability, regulatory foresight, and evidence generation for real-world clinical utility will gain advantage. Investments in longitudinal clinical data collection, health economics analyses, and payer engagement strategies are increasingly essential to support adoption beyond early-adopter settings. Ultimately, success depends on aligning scientific innovation with pragmatic commercialization pathways and robust operational models that can deliver consistent quality at clinical scale.

Action-oriented recommendations to integrate multi-analyte science, resilient supply chains, and payer-aligned evidence generation into executable commercialization roadmaps

Industry leaders should pursue a set of actionable priorities that align scientific capability with regulatory readiness and commercial execution. First, prioritize multi-analyte approaches that combine genetic, proteomic, and metabolic signals to enhance diagnostic precision and to address tumor heterogeneity. By designing assays with complementary modalities, organizations can increase clinical relevance and reduce reliance on single-analyte decision points. Second, invest in data infrastructure and bioinformatics pipelines that support scalable interpretation, federated data sharing, and the incorporation of machine learning models, while maintaining rigorous data governance and privacy safeguards.

Third, build robust supplier diversification and near-shore manufacturing strategies to mitigate trade-related disruptions and to preserve supply chain continuity. Fourth, align clinical validation programs with regulatory expectations and payer evidence requirements from the outset by engaging regulators and reimbursement stakeholders early, and by embedding health economics and outcomes research into pivotal studies. Fifth, pursue strategic partnerships with academic centers, contract research organizations, and clinical consortia to access diverse patient cohorts and to accelerate real-world evidence generation. Finally, develop flexible commercial models that accommodate centralized and decentralized testing workflows, and that offer value-based contracting and outcome-linked reimbursement structures where appropriate.

Taken together, these recommendations form an integrated roadmap: combine technological breadth with data excellence, operational resilience, early regulatory engagement, and collaborative clinical programs to convert biomarker innovation into sustained clinical and commercial impact.

A transparent triangulated research methodology combining stakeholder interviews, peer-reviewed literature, and regulatory guidance to support robust and actionable insights

This research synthesis relies on a triangulated methodology that combines primary qualitative interviews, secondary literature review, and structured synthesis of regulatory and clinical guidance. Primary inputs included discussions with stakeholders across translational research, diagnostic development, clinical laboratory operations, and payer advisory roles to capture practical constraints and strategic priorities. Secondary sources comprised peer-reviewed literature, public regulatory guidance, clinical trial registries, and technical white papers to ensure scientific accuracy and to contextualize technological capabilities.

Analysis emphasized cross-validation of findings by comparing independent data streams and by reviewing methodological assumptions for potential bias. Where possible, evidence pertaining to analytical validity, clinical utility, and implementation barriers was corroborated across multiple sources to strengthen confidence in conclusions. Limitations include variability in publicly available clinical performance data and the rapid pace of technological evolution, which necessitates ongoing monitoring. To mitigate these limitations, the methodology incorporated expert adjudication and scenario planning to reflect plausible operational responses under different regulatory and supply chain conditions.

The final synthesis presents integrative insights designed to inform strategy without purporting to replace detailed, product-specific validation studies. Users seeking bespoke analyses are encouraged to commission targeted primary studies aligned with their specific product development plans and regulatory jurisdictions.

A concise conclusion linking integrated scientific approaches, operational resilience, and evidence-driven strategies as the decisive factors for future success in biomarker development

In summary, the cancer biomarker domain stands at a pivotal inflection point where scientific innovation, technological convergence, and commercial pragmatism must align to realize clinical value. The most promising advances arise from integrated approaches that leverage genetic, proteomic, metabolic, and cellular signals, combined with platform technologies that deliver reproducible, interpretable results across clinical settings. At the same time, external factors such as trade policy, regional regulatory differences, and payer expectations exert decisive influence on how and where innovations are adopted.

Therefore, organizations seeking to lead should adopt holistic strategies that integrate multi-analyte assay design, robust data and analytics capabilities, supply chain resilience, and early payer engagement. Collaborative models that connect academic discovery with commercial development and clinical operational expertise will accelerate translation. Ultimately, success will depend on the ability to generate compelling clinical evidence, to navigate regional regulatory and reimbursement landscapes, and to operationalize high-quality laboratory workflows that deliver timely, actionable results for clinicians and patients.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer Biomarkers Market, by Biomarker Type

  • 8.1. Cellular Biomarker
  • 8.2. Genetic Biomarker
    • 8.2.1. DNA Biomarker
    • 8.2.2. Epigenetic Biomarker
    • 8.2.3. RNA Biomarker
      • 8.2.3.1. Long Non-Coding RNA
      • 8.2.3.2. Messenger RNA
      • 8.2.3.3. MicroRNA
  • 8.3. Metabolic Biomarker
  • 8.4. Protein Biomarker

9. Cancer Biomarkers Market, by Technology

  • 9.1. Enzyme Linked Immunosorbent Assay
  • 9.2. Flow Cytometry
  • 9.3. Mass Spectrometry
  • 9.4. Next Generation Sequencing
  • 9.5. Polymerase Chain Reaction

10. Cancer Biomarkers Market, by Cancer Type

  • 10.1. Breast Cancer
  • 10.2. Colorectal Cancer
  • 10.3. Lung Cancer
  • 10.4. Ovarian Cancer
  • 10.5. Prostate Cancer

11. Cancer Biomarkers Market, by Test Type

  • 11.1. Liquid Biopsy
  • 11.2. Tissue Biopsy

12. Cancer Biomarkers Market, by Application

  • 12.1. Companion Diagnostics
  • 12.2. Diagnostics
  • 12.3. Monitoring
  • 12.4. Predictive Testing
  • 12.5. Prognostics

13. Cancer Biomarkers Market, by End User

  • 13.1. Academic Research Institutes
  • 13.2. Biotechnology Companies
  • 13.3. Contract Research Organizations
  • 13.4. Diagnostic Laboratories
  • 13.5. Hospitals
  • 13.6. Pharmaceutical Companies

14. Cancer Biomarkers Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Cancer Biomarkers Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Cancer Biomarkers Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Cancer Biomarkers Market

18. China Cancer Biomarkers Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. Agilent Technologies, Inc.
  • 19.7. Bio-Rad Laboratories, Inc.
  • 19.8. bioMerieux SA
  • 19.9. Caris Life Sciences
  • 19.10. Exact Sciences Corporation
  • 19.11. F. Hoffmann-La Roche Ltd
  • 19.12. Foundation Medicine, Inc.
  • 19.13. Guardant Health, Inc.
  • 19.14. Hologic, Inc.
  • 19.15. Illumina, Inc.
  • 19.16. Myriad Genetics, Inc.
  • 19.17. Natera, Inc.
  • 19.18. NeoGenomics Laboratories, Inc.
  • 19.19. PerkinElmer, Inc.
  • 19.20. QIAGEN N.V.
  • 19.21. Quest Diagnostics Incorporated
  • 19.22. Siemens Healthineers AG
  • 19.23. SomaLogic, Inc.
  • 19.24. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANCER BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CANCER BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CELLULAR BIOMARKER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CELLULAR BIOMARKER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CELLULAR BIOMARKER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY DNA BIOMARKER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY DNA BIOMARKER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY DNA BIOMARKER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY EPIGENETIC BIOMARKER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY EPIGENETIC BIOMARKER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY EPIGENETIC BIOMARKER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY LONG NON-CODING RNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY LONG NON-CODING RNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY LONG NON-CODING RNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY MESSENGER RNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY MESSENGER RNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY MESSENGER RNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY MICRORNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY MICRORNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY MICRORNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY METABOLIC BIOMARKER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY METABOLIC BIOMARKER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY METABOLIC BIOMARKER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PROTEIN BIOMARKER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PROTEIN BIOMARKER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PROTEIN BIOMARKER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY OVARIAN CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY OVARIAN CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY LIQUID BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY LIQUID BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TISSUE BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TISSUE BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TISSUE BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PREDICTIVE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PREDICTIVE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PREDICTIVE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PROGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PROGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PROGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. GCC CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. GCC CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. GCC CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 195. GCC CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 196. GCC CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. GCC CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. GCC CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. GCC CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 200. GCC CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. G7 CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. G7 CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. G7 CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 222. G7 CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 223. G7 CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 224. G7 CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. G7 CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. G7 CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 227. G7 CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. NATO CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. NATO CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. NATO CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 231. NATO CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 232. NATO CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 233. NATO CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. NATO CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. NATO CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 236. NATO CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)